NBCD
NBCD is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee
Sponsor Latigo Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients with Inflammatory Knee Osteoarthritis (KOA).
Sponsor Peptinov
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients with Primary Knee Osteoarthritis
Sponsor Enlivex Therapeutics Ltd.
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-336 as an Adjunct to Diet and Exercise in Obese Individuals with Osteoarthritis of the Knee
Sponsor KeyBioscience S.A.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 3.06% in the Treatment of Pain and Symptoms of Knee Osteoarthritis
Sponsor Amzell B.V.
- Start (EU)
- Latest update
- Estimated end
A placebo-controlled, double-blinded, randomized, dose-finding trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritis
Sponsor Akl Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
Sponsor Synact Pharma ApS
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
Sponsor Pliant Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-001 in Patients with Osteoarthritis of the Knee
Sponsor Latigo Biotherapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for NBCD?
The 2026-10-09 snapshot links NBCD to 9 distinct CTIS trials. Recorded services include Clinical monitoring, Data management, Electronic data capture, Investigator recruitment, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for NBCD?
The most frequently recorded therapeutic areas are Musculoskeletal, Pain Medicine. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to NBCD conducted?
The linked trials record locations in 13 countries, including Denmark, Poland, Czechia, Romania, France. These are trial locations, not confirmed office locations or countries where NBCD delivered services.
What can this page tell me about NBCD's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under NBCD. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- NBCD A/S